Literature DB >> 6691363

Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease.

J D O'Duffy, D M Robertson, N P Goldstein.   

Abstract

Among 21 patients with Behçet's disease, the results of various treatments were assessed. Treatment with chlorambucil, 0.1 mg/kg daily, compared favorably with corticosteroids. Uveitis and visual acuities improved in five of seven eyes when the patients were treated with chlorambucil, whereas improvement was observed in only four of 13 eyes when treatment consisted of corticosteroids. In 19 treatment courses among 14 patients with meningoencephalitis or recurrent meningitis, eight of nine patients treated with chlorambucil had remission of their disease; eight of 10 treatment courses with other agents--generally, corticosteroids--failed to induce remission in any of eight patients. Elevated cerebrospinal fluid cell counts returned to normal in five of nine patients treated with chlorambucil but remained elevated in five of six patients treated with corticosteroids. Two patients died, one who was taking prednisone plus cyclophosphamide and the other after prednisone plus multiple immunosuppressive treatments. Toxicity from chlorambucil included leukopenia (two patients), thrombocytopenia (one), bronchopneumonia (one), and amenorrhea (two). The duration of chlorambucil therapy averaged 1.8 years both for patients with uveitis and for those with meningoencephalitis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6691363     DOI: 10.1016/0002-9343(84)90753-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  27 in total

Review 1.  Behçet's disease: immunopathologic and therapeutic aspects.

Authors:  Robert Meador; George Ehrlich; Joan M Von Feldt
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

Review 2.  Behçet's disease.

Authors:  V Kontogiannis; R J Powell
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

3.  Behçet's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-09       Impact factor: 3.598

4.  Behçet's disease.

Authors:  G P Clunie
Journal:  BMJ       Date:  1992-05-30

Review 5.  Immunosuppressive therapy in autoimmune disease--a review.

Authors:  T J Counihan; C Feighery
Journal:  Ir J Med Sci       Date:  1991-07       Impact factor: 1.568

6.  Behçet's Disease.

Authors:  Gulsen Akman-Demir; Sabahattin Saip; Aksel Siva
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

Review 7.  Pharmacotherapy of scleritis: current paradigms and future directions.

Authors:  Robert M Beardsley; Eric B Suhler; James T Rosenbaum; Phoebe Lin
Journal:  Expert Opin Pharmacother       Date:  2013-02-21       Impact factor: 3.889

Review 8.  The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis.

Authors:  Aksel Siva; Sabahattin Saip
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

9.  Treatment of Behçet's disease with thalidomide.

Authors:  M H Hamza
Journal:  Clin Rheumatol       Date:  1986-09       Impact factor: 2.980

10.  Rapid, complete and sustained response to corticosteroids and pulse cyclophosphamide therapy in a patient with behçet and central nervous disease.

Authors:  Concepción M Nuñez-Sotelo; Luis A Gutiérrez-Gonzalez; Martín A Rodriguez
Journal:  Maedica (Buchar)       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.